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Abstract
Background: The ability of health organizations in developing countries to expand access to
quality services depends in large part on organizational and human capacity. Capacity building
includes professional development of staff, as well as efforts to create working environments
conducive to high levels of performance. The current study evaluated an approach to public-private
partnership where corporate volunteers give technical assistance to improve organizational and
staff performance. From 2003 to 2005, the Pfizer Global Health Fellows program sent 72
employees to work with organizations in 19 countries. This evaluation was designed to assess
program impact.
Methods: The researchers administered a survey to 60 Fellows and 48 Pfizer Supervisors. In
addition, the team conducted over 100 interviews with partner organization staff and other key
informants during site visits in Uganda, Kenya, Ghana, South Africa and India, the five countries
where 60% of Fellows were placed.
Results: Over three-quarters of Fellowships appear to have imparted skills or enhanced
operations of NGOs in HIV/AIDS and other health programs. Overall, 79% of Fellows reported
meeting all or most technical assistance goals. Partner organization staff reported that the Fellows
provided training to clinical and research personnel; strengthened laboratory, pharmacy, financial
control, and human resource management systems; and helped expand Partner organization
networks. Local staff also reported the Program changed their work habits and attitudes. The
evaluation identified problems in defining goals of Fellowships and matching Organizations with
Fellows. Capacity building success also appears related to size and sophistication of partner
organization.
Conclusion: Public expectations have grown regarding the role corporations should play in
improving health systems in developing countries. Corporate philanthropy programs based on
"donations" of personnel can help build the organizational and human capacity of frontline agencies
delivering health services. More attention is needed to measure and compare outcomes of
international volunteering programs, and to identify appropriate strategies for expansion.
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As international donors expand global financing in
response to the HIV-AIDS pandemic and in support of the
Millennium Development Goals, issues of human and
organizational capacity are becoming increasingly impor-
tant [1]. Governmental and non-governmental organiza-
tions alike are dealing with important capacity constraints
which prevent services from being delivered in sustainable
ways. Challenges include highly visible constraints on
number, distribution, and training of service delivery
staff, especially in countries hardest hit by the HIV-AIDS
epidemic [2-4]. Less visible, but no less important, are
capacity problems related to health systems operational
efficiency, productivity, process improvement, and sus-
tainability [5]. The capacity to continuously address new
problems and improve access to quality health services
requires not only financial and material inputs, but also
investments in leadership development, management,
and service delivery systems improvement [6,7].
The private business sector is recognized as an important
stakeholder in international development, especially in
the health sector. Public-private partnerships are being
pursued as a way to leverage ideas, resources, and capabil-
ities to achieve public health goals [8]. Most commonly,
business sector contributions to capacity building in the
health sector have included philanthropic donations of
essential inputs such as drugs and financial resources [9-
11]. Research-based pharmaceutical companies gave over
$564 million in donations to developing countries in
2001 [12], and drug donation programs launched by
Merck, SmithKline Beecham, Pfizer, and Beckton Dickin-
son have been helpful in improving access to health care
for more than 248 million people [13]. Drug donation
programs have strengthened organizational capacity for
communicating and collaborating with development
partners, and helped to develop new systems for drug dis-
tribution and monitoring & evaluation. At the same time,
however, such programs may pose challenges in regard to
ownership, accountability, and respect for due process [9].
In workshops organized by the Global Health Initiative of
the World Economic Forum to discuss how business can
help strengthen service delivery capacity in Sub-Saharan
Africa, management was identified as a key challenge
amenable to solutions sought in partnership with busi-
ness [6]. One type of program designed to build manage-
ment capacity for service delivery in developing countries
is international volunteering. Traditionally organized by
professional, faith-based, and non-profit organizations
[14], volunteering programs are increasingly being offered
by businesses, either alone or in association with other
businesses [15,16]. For example, the Brookings Institute
recently created an Initiative on International Volunteer-
ing and Service with representatives from major multina-
tional corporations such as IBM, Microsoft and Pfizer
[17]. In Europe, public-private partnerships such as the
Netherlands PUM program and the Dutch Employers
Cooperation Programme (DECP) have been fielding busi-
ness volunteers to build capacity of local business organi-
zations in developing countries [18,19], while the
international transportation giant TNT has had a public-
private partnership with the UN World Food Programme
since 2002, offering technical specialist volunteers for up
to one year to help build capacity through knowledge
transfer, mentoring, and other projects [20]. Yet, little is
known about the impact of these programs on organiza-
tions receiving assistance, especially in the developing
world.
In 2005, Boston University's Center for International
Health and Development was asked by the U.S. Agency
for International Development (USAID) and Pfizer Cor-
poration to undertake an evaluation of Pfizer's interna-
tional volunteering program. From 2003 to 2005, Pfizer's
Global Health Fellows (GHF) Program placed 72 employ-
ees in organizations based in 19 countries. The goal of the
program was to promote better health by improving the
service delivery capacity of local partners in poor coun-
tries. The Boston University research team sought to deter-
mine the impact of Pfizer's international volunteering
program on the organizations receiving assistance, and to
document lessons learned for public-private collabora-
tion in capacity building.
Program history and structure
Pfizer's Global Health Fellows Program matches qualified
and interested Pfizer staff with assignments in local part-
ner organizations in the developing world. The Program
identifies potential local partners and Fellowship assign-
ments through intermediary non-governmental organiza-
tions (NGOs) such as Health Volunteers Overseas (HVO)
and American Jewish World Services (AJWS). Pfizer also
works directly with large international NGOs such as
Family Health International, Médecins du Monde, and
other partner organizations such as the Uganda Infectious
Disease Institute.
Twice a year, Pfizer employees apply for selection as Fel-
lows through a competitive process. The approval of a fel-
low's supervisor must be obtained in order for them to
participate in the program, which implies that the Fel-
low's work will be covered while overseas. The Pfizer work
unit Supervisor is not responsible for the matching proc-
ess or program impact, though Supervisors communicate
with Fellows during the Fellowship.
Partner Organizations review Fellowship candidates for a
defined assignment, and select a Fellow from the candi-
date pool. Fellows receive pre-departure training andPage 2 of 11
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competence, and GHF Program procedures. They also are
encouraged to contact the Partner Organization to discuss
their scope of work prior to arrival.
Assignments average three to six months. The fellow's sal-
ary and benefits are charged to her/his Pfizer work unit,
while living allowance and travel are paid by Pfizer Cor-
porate Philanthropy, which also pays a small allowance to
the Partner Organization for supervision. Subject to
approval, the Fellow may also use up to $500 to cover
material costs for local projects.
Figure 1 shows the geographic distribution of Fellowships
as of October 2005, illustrating the concentration of Fel-
lows in Sub-Saharan Africa (60%).
Evaluation design
Conducted between October 2005 to January 2006, the
evaluation sought to answer the following questions:
▪ How do Fellowships affect the Partner Organizations
with which Fellows are placed? How does the Fellowship
Program build institutional and professional capacity?
The evaluation also examined how the Fellowships affect
participating Pfizer employees and their work units, and
examined the effect of the Global Health Fellows Program
on Pfizer's reputation and corporate activities (findings
presented elsewhere) [21]. This article presents the find-
ings related solely to the impact on Partner Organizations.
Methods
The evaluation team used both qualitative and quantita-
tive methods to collect data. Two approaches were used: a
survey for eliciting information from Fellows and Pfizer
Supervisors, and structured in depth interviews to gather
information from Partner Organizations. The diversity of
respondents within Partner Organizations (co-workers,
supervisors, program directors, and beneficiaries, among
others) made it difficult to use the survey approach. We
also wanted to explore perceptions of program goals and
impact in more detail through the in-depth interviews
with Partner respondents. The study design was approved
by the Boston University Medical Campus Institutional
Review Board.
Fellow and supervisor surveys
We surveyed Fellows (both returned and current as of Jan-
uary 2006) and the Pfizer Supervisors of Fellows. We
attempted to contact all 72 Fellows and 69 Supervisors
who had participated in the program as of October 2005,
including those who had subsequently left the company.
Our response rates were 83% (60) for Fellows and 70%
(48) for Supervisors. Fifteen of the 33 non-respondents
did not answer repeated e-mails and phone messages, 14
had missing contact information, and 4 were interviewed
too late to be included in the analysis. About 72% of Fel-
lows interviewed were female, which is the same percent-
age as in the total population of Fellows. Interviews were
conducted in person or by telephone. The survey ques-
tions were arranged by phase of fellowship (prior to, dur-
ing, and post) with questions to elicit suggestions and
Geographic distribution of Pfizer Global Health Fellows as of October 2005Figure 1
Geographic distribution of Pfizer Global Health Fellows as of October 2005.
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dentiality was assured by using codes to identify respond-
ents, and by masking identifying detail from qualitative
responses.
Fellows were asked questions about preparation, goals
and scope of work, achievements, and impact of the pro-
gram on themselves, the Partner Organization, their Pfizer
workgroup, and the company as a whole. Supervisors of
Fellows were asked about reasons for approving the Fel-
lowship, preparation, how work was covered in the Fel-
low's absence, and the impact of the program on the
Fellow, the Pfizer workgroup, and the company. Partner
Organization respondents were asked about goals and
scope of work, achievements, and the impact of the pro-
gram on the Partner Organization, and their impressions
of the company.
Qualitative data from the surveys were entered into NVivo
2.0 software. NVivo is a computer program that allows for
more complex categorization of large sets of qualitative
data than when done manually. Domain analysis was
subsequently conducted by a research team member and
assistant. Quantitative data were analyzed using Microsoft
Excel and SAS v9.1 to produce frequency tables and means
where appropriate. Data were stratified by round of Fel-
lowship and current versus returned Fellows to elicit
trends.
NGO Partner interviews
Researchers also interviewed personnel from Partner
Organizations in Kenya, Uganda, Ghana, South Africa,
and India – countries which represented 60% of Fellow-
ships. We interviewed the manager of the Organization
where each Fellow was placed, the Fellow's immediate
Supervisor, and co-workers. In a limited number of cases,
we were able to interview local recipients of the services
the Fellow was attempting to improve. For many Fellow-
ships, we visited the work site and in some cases reviewed
the systems changes resulting from the Fellow's recom-
mendations.
In total, the research team conducted over 100 NGO Part-
ner interviews. Members of the evaluation team wrote
notes from each interview, and all references to individual
Fellows were coded using the same coding system used to
identify Fellow interviews. In order to encourage full dis-
closure, respondents were promised that feedback on
individual Fellows would not be shared with the Fellow or
with Pfizer except as part of our aggregate findings. The
interview notes were shared with all five members of the
study team. Where appropriate, respondent's impressions
of Fellowship accomplishments were compared with
statements made by the Fellows. This comparison has
informed our general conclusions, but no specific con-
trasts are shown in our results in order to maintain confi-
dentiality.
The evaluation team met after completion of all field
interviews to formulate general conclusions from the
interview material. In our discussions, we developed cate-
gories for grouping Fellowships, based on level of skill/
judgment applied by the Fellow and the level of impact on
the host organization and the services it provides. This
process is described in more detail in the Results section.
Results
Fellowship goals
Knowledge transfer was an overriding theme in Fellows'
statements of their professional goals, while on a personal
basis many Fellows noted a desire to "do good", serve the
poor, and to grow personally. Fellows described their
intention to make a positive impact on the Partner
through transferring their expertise. Fellows also
described what they believed were their Partner Organiza-
tion's goals, which the research team grouped into six
broad categories, shown in Table 1. Most commonly, Part-
ner goals focused on management systems improve-
ments, assistance in organizational planning, training,
and evaluation.
Nine Fellows (15%) mentioned that the Partner goals
were undefined or left entirely to the Fellow to develop,
and 21 Fellows (35%) described how the goals were rede-
fined or expanded during the Fellowship. For example,
one Fellow remarked, "Once they realized I could do
more they asked me to help with research. I wrote grant
proposals and one was approved." Another stated "I sat
down and said, 'I think I can do more' and wrote a whole
set of goals ... and I added indicators for success."
On the other end of the spectrum were Fellowships that
were overly ambitious, with too many tasks specified for
the time and resources available or skill capacity of the
Fellow. One Fellow was given a "laundry list that would
have taken someone three years," while another men-
tioned partner goals changed "on a daily basis". Four Fel-
lows mentioned that they narrowed the scope of the goals
during the Fellowship.
Fellows' perceptions of accomplishments
The diversity in Fellowship goals made it difficult to eval-
uate the Fellowships against a common standard. Instead,
we focused on documenting Fellows' perceptions of goal
accomplishment, perceived effects of the Fellowship
expressed by Partners, and observed effects or documenta-
tion available during our site visits.
First, we asked Fellows to report on how well they thought
they had achieved Partner Organization goals (see TablePage 4 of 11
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achieved "all" Partner goals, while an additional 20
(33%) reported having achieved "most" goals. Only one
Fellow (2%) felt none of the Partner's goals for the Fellow-
ship had been achieved. Where Fellowship goals were
modified during the Fellowship, we asked Fellows to eval-
uate their accomplishment against the amended goals.
Through open-ended questions, we sought to understand
what Fellows believed were the most important effects
that their Fellowships had on Partners. Fellows com-
monly mentioned three types of benefits:
▪ improved morale and increased pride in work on the
part of Partner Organization staff;
▪ shifts to more strategic or business thinking (i.e. chang-
ing how Partners' viewed their target populations, project
priorities, or systems needs);
▪ stronger technical or management capacity of the Part-
ner Organization (i.e. enabling a new activity or improv-
ing existing activities).
As shown in the next section, data collected from NGO
respondents supported these findings.
Partner perceptions of accomplishments
Interviews with respondents at Partner Organizations pro-
vided examples of how Fellows helped organizations
develop greater professional pride, confidence and self-
efficacy, a "systems way of thinking" and business
approach to management, and new technical skills. NGO
perceived benefits from the Fellowships are discussed in
three areas: skills transfer, operational improvements, and
attitudes.
According to Partner Organization respondents, Pfizer
Fellows transferred skills in the areas of medical practice,
nursing, pharmacology, laboratory science, computer
technology, facility and equipment maintenance, finan-
cial systems, epidemiology and biostatistics, marketing,
program evaluation, and design and management of clin-
ical research trials. These skills were transmitted in a vari-
ety of ways. Some Fellows were assigned to academic
institutions, where they helped local faculty with curricu-
lum development and actually taught classes and semi-
nars on topics not previously covered. Others provided on
the job training, often as part of an assignment to develop
a particular product or operational improvement. Fellows
sometimes taught computer skills by showing counter-
parts how to use an office application such as PowerPoint
for their work, or by teaching a statistics application.
On the clinical research side, Fellows helped to write
research grant proposals, design clinical trials, and train
staff in proper trial procedures. For example, respondents
in one Partner Organization attributed a newfound ability
to compete for grants (demonstrated by two grants sub-
mitted and one funded) to the work of a Fellow. In
Table 2: Fellows reporting on goal accomplishment
Proportion of NGO goals achieved: Number %
All 28 46%
Most 20 33%
Some 8 13%
Few 2 3%
None 1 2%
Don't know 2 3%
Table 1: NGO Partner goals as articulated by Global Health Fellows
Category Illustrative goals Number (%) of Fellows who said this was an NGO goal
Management and planning Strengthening management of facilities, systems, or data; 
process or quality improvement; strategic, organizational 
or human resources planning; communication or marketing 
plan development
20 (34%)
Training and education Mentoring; training NGO staff; teaching students; 
educating community members
19 (32%)
Documentation Writing or revising Standard Operating Procedures (SOP) 
or best practices; grant writing; producing publications
17 (29%)
Evaluation Evaluate an existing or proposed program; conduct 
assessment of staff
12 (20%)
Technical or scientific capacity building Software installation, database creation, laboratory or 
clinic set up; and research capacity development
9 (15%)
Promotion/external Relations Public relations; creating a development office; networking 9 (15%)
multiple goals possible in one FellowshipPage 5 of 11
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agement systems that organized and streamlined work,
and could easily be modified to accommodate different
study protocols in the future.
Turning to operational improvements in administrative
and clinical care systems, most Partner Organization
respondents readily cited operational changes that came
from the work of the Fellows. Often the Fellow worked
with an individual or team, using a combination of tech-
nical knowledge and management techniques to design
and implement changes. For example, in a large, private
non-profit teaching hospital, a sequence of two Fellows
with extensive pharmacy operating experience worked
with senior pharmacy staff to design a new system for
recording drug procurement transactions; a drug pricing
system with lower mark-ups on expensive drugs to make
these more affordable to some seriously ill patients; and
staffing changes based on standard productivity measures
to reduce waiting time and increase client through-put.
The Fellows also helped pharmacy staff to work with the
Information Technology department to integrate neces-
sary changes into the hospital's computerized systems.
The Pharmacy Director described the effect of the new
procedures: "I used to spend up to four hours a day sign-
ing documents. I brought them with me to meetings.
When I signed one pile, it was replaced by another. Now
it is reduced to nearly nothing. [The Fellow] has freed me
to develop the Department." Examples of other opera-
tional changes are shown in Table 3.
A wide variety of work products were produced by the Fel-
lows, including standard operating procedures, policy
manuals, problem analysis documents (e.g. SWOT analy-
sis and flow charts), and treatment protocols. In some
cases, these depended on the Fellow's professional exper-
tise. At one Partner, codification of procedures enabled
the Organization to apply for formal accreditation for its
services. Some Partner Organizations were able for the
first time to address issues (such as development of a pub-
lic relations strategy) because the Fellow provided the first
available expertise in this area.
In other cases, the product was not dependent on a
unique skill. The Fellow had the time and writing ability
to prepare documents within the professional compe-
tence of existing staff, but which NGO personnel did not
have the time to prepare. Fellows also taught counterparts
how to write better reports. "I learned how to write a
report systematically....this is a format we can use for all
our work," said one counterpart.
In a few cases, a Fellow provided energetic volunteer
assistance, relatively unrelated to the Fellow's expertise, in
carrying out the mission of the Partner Organization. The
Fellow's determination and hard work enabled the Organ-
ization to improve or expand its service while the Fellow
was present. For example, one volunteer organized local
artists to decorate drab pediatric wards with bright murals.
Another organized a major community clean-up opera-
tion, even raising some of the funds for equipment. The
community was still cleaner than usual six months after
the Fellow's departure. However, with no clean up tools
regularly available, it may be difficult to maintain the
community spirit the Fellow engendered.
Finally, although the impact is more difficult to quantify,
Partner Organization personnel offered examples of ways
in which Fellows changed attitudes and stimulated new
approaches to problem solving. For example,
Networking
Fellows demonstrated the value of networking and reach-
ing out to development partners. To better serve an
impoverished rural population, one Fellow suggested that
the NGO approach the local government health depart-
ment to urge expansion of in-village HIV counselling and
testing. These negotiations led the government to take
Table 3: Examples of accomplishments of fellowships
Organization Operational Change Effect
NGO scientific research and clinical care 
facility
Creation of preventive maintenance schedules 
and routines, including budgets for necessary 
replacement parts
Equipment in working order, with sufficient 
budget for repairs and maintenance
NGO clinical research organization Training in research methods, design of clinical 
trial management systems, grant writing 
assistance
Submission of research grants obtaining new 
sources of funding
NGO service delivery organization Development of a financial system to track cost 
and budget at multiple new facilities, and to 
meet donor reporting requirements
Increased services delivered and revenues 
received
NGO teaching hospital Revision of pharmacy operating procedures 
and pricing policies; creation of staff 
productivity measures; quality improvement 
teams
Reduced paperwork; better aligned prices with 
cost and patient ability to pay; reduced waiting 
timesPage 6 of 11
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than forcing villagers to individually incur transport costs
to reach the urban VCT center. In another country, a Fel-
low introduced NGO staff to a government office which
had grant revenue and was looking for projects to fund,
while also connecting the NGO to a local University look-
ing for opportunities to involve student and faculty volun-
teers in community service projects.
Business perspective
Fellows convinced Organizations of the need to measure
and continuously evaluate interventions, with Fellows
actually working to draw up evaluation plans. Fellows
suggested ways to measure the impact of social marketing
programs, and to assess productivity and objectively
assess staff performance. One respondent explained, "
[The Fellow] analyzed work efficiency. We didn't know
how to manage our own productivity before. We did not
know how to justify new staff. Now we can justify.....Def-
initely, the changes will be lasting."
Individual initiative
Fellows stimulated initiative in their counterparts. One
respondent said " [The Fellow] taught us to be responsi-
ble. We used to wait for higher authority to tell us what to
do. [The Fellow] told us that the whole responsibility
should be ours. Our talents, feelings, ideas can be brought
out in our work.... Now, we don't postpone things so
much, and it helps to avoid having things clump up.
When we start something, we finish it."
Teamwork and time management
Fellows encouraged counterparts to work in teams, and to
plan and monitor their own work. Work organization
often improved as a result of the Fellows' example. An
employee in one organization noted: "I learned time
management. We would have a plan that said when we
were to do things, and then we did them according to the
plan. That wasn't the way we worked before."
Fellowship problems
A few Fellowships ran into problems because of personal-
ity clashes, lack of effort on the part of the Fellow, and cul-
ture shock. These problems may be mitigated through
careful selection, training, and matching of Fellows to
Organizations. Other problems generally contributing to
the lack of success in achieving Fellowship goals included:
▪ The Fellow did not have the skill set expected by the host
organization;
▪ The Terms of Reference for the Fellowship were vague or
inaccurate;
▪ Critical prerequisites–computer software or hardware, or
a key counterpart–were not available when the Fellow
arrived;
▪ Access to critical counterparts in the organization was
too limited. The chosen counterpart may have been too
high or too low in the organization;
▪ Counterparts were not able to prioritize the Fellow's
assignment. This may have been a result of excessive rou-
tine work load, poor motivation, or the failure to involve
the work unit in defining the need for a Fellow;
▪ The Partner Organization did not have the management
or financial flexibility to implement the Fellow's recom-
mendations.
Typology of fellowship impact
A key question of concern to Pfizer and USAID was
whether the Global Health Fellows Program was having
an impact on service expansion in the countries and
organizations where it was working. To answer this ques-
tion, the research team attempted to define a typology
delineating three main levels of Fellowship impact. The
typology is presented in Table 4.
By reviewing data from Fellows, Supervisors, and (in the
five countries visited) Partner Organizations, the research
team was able to place most Fellowship assignments
within this typology. As the typology model was created at
the end of the study, we did not measure the constructs
explicitly during the research process; consequently, the
model's reliability is not yet established. Despite this lim-
itation, we present the typology to illustrate a potential
avenue for empirical evaluation of corporate volunteering
programs in the future.
A change in operations based on the Fellow's work, and
which facilitated the sustained expansion of services, was
classified as Type 3. Thirty-one percent of Pfizer Fellow-
ships fell into this category. For example, one Fellow's
work resulted in an increase in the volume of CD4 tests [a
test of the immune function, used for HIV/AIDS care] per-
formed by the Partner Organization, from 100 to 300 a
day, while simultaneously increasing test quality and reli-
ability. At another Partner Organization, a Fellow created
an accounting software application for revenue reporting
which saved staff six working hours per week while
accommodating a tripling in the amount of revenues
recorded.
Fellowships were classified as Type 2 if they involved
transfer of skills and expertise through teaching, or the
development of documents such as clinical protocols.
These capacity building activities were perceived as impor-Page 7 of 11
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for these Fellowships there was less evidence that expan-
sion had occurred yet. Almost half of Fellowships (48%)
were categorized as Type 2.
A volunteer effort not based on the special skill and exper-
tise of the Pfizer employee, and not transferring scarce
skills to the Partner, was classified as Type 1.
Thirteen percent of Fellowships fell into Type 1, while an
additional 8% of Fellowships lacked sufficient data for
classification.
The research team found an increased number of Type 3
Fellowships in later rounds of the program, although the
difference was not statistically significant. If real, such a
difference could reflect the increased attention to defining
specific goals and objectives for the Fellow's scope of work
early in the assignment, which involved more communi-
cation with Partner Organization staff prior to the Fel-
low's arrival. When comparing current versus returned
Fellows, we did not observe differences in Fellowship
type, and there were no significant differences between
Fellowship performance according to the region of the
world where the Fellow worked. We did note an associa-
tion between Fellowship length and performance, with
longer Fellowships scoring higher. While the association
did not reach statistical significance, this finding seems
important. A possible confounder could be program tim-
ing: more of the shorter length Fellowships were held in
the first year of the GHF program, when the program
design and management systems were still being refined.
Discussion
The evaluation results raise important operational, strate-
gic, and methodological questions. Operational issues are
addressed first, followed by a discussion of more general
strategic questions concerning the design of international
corporate volunteering programs. The last section dis-
cusses methodological concerns, and suggests steps
needed to improve future design and implementation of
programs.
Operational issues
Corporations seeking to contribute resources to global
health and development through public-private partner-
ships using corporate volunteering should consider les-
sons learned from the Pfizer experience. For example, the
Pfizer program demonstrates the need to define Fellow-
ship assignments with specific technical assistance goals
and tasks, in order to make the best match between volun-
teer employees and the Partner Organizations. Prerequi-
sites for assignments (including necessary software or
staff) should be in place before Fellows are sent, and
assigned counterparts must have sufficient time and deci-
sion making authority to support the Fellowship goals.
As other researchers have noted, philanthropic partner-
ships in the developing world need to be sure that volun-
teers are prepared for different cultural and social decision
making processes, language differences, and unfamiliar
bureaucracy [13]. Pfizer has developed effective orienta-
tion programs for Fellows which could serve as a model
for other companies. For example, over time, Pfizer has
adjusted the security and health briefings to incorporate
examples and experiences of Fellows in the field. These
programmatic adjustments and training concerns are not
unlike those needed to maximize other types of donor-
funded or development bank technical assistance initia-
tives.
The research team was surprised by the large percentage of
women participants in the Pfizer program, a figure dispro-
portionate to Pfizer's distribution of professionals eligible
for participation. Pfizer staff could not give reasons for
this discrepancy, but it may be because women are more
likely to participate in any type of volunteering effort [22].
In addition, the program is not explicitly linked to man-
Table 4: Typology of Pfizer corporate volunteering Fellowships
Type 1 Accomplishments limited. Fellow provided volunteer assistance not requiring fellow's professional training and not building on expertise 
acquired through employment at Pfizer. The skills applied are available in-country or from many other international volunteers. Clients of the 
partner organization may have benefited from Fellow's personal efforts, but there was little or no permanent change in the ability of the partner 
organization of its staff to deliver services.
Type 2 Fellow provided technical expertise or training, based on fellow's professional training or Pfizer acquired expertise, which resulted in 
upgrading the skills of staff in the partner organization, or design of tools/methods for future changes. This may include creation of teaching 
curriculum, clinical guidelines and protocols, standard operating procedures as well as on-the-job and classroom training. No obvious effect on 
volume of services, but provided ground work for future improvements or increases in services, and quality may be improved.
Type 3 Using professional skills and/or Pfizer acquired expertise, Fellow worked with counterparts to introduce an operational or managerial 
improvement that will result in expanding services of the organization. Used skills or expertise not generally available in country. The quantity of 
service is increased directly, or as a result of improved efficiency/lowered unit cost of a service. May include changes in the organization and work 
ethic of a partner organization if these are directly attributable to the Fellow's effort and translate into sustainable service expansion.Page 8 of 11
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make it appear to be a "side track" from a standard corpo-
rate career advancement track.
Strategic issues
Consideration of gender imbalance leads to more strategic
considerations of program design. One of these issues is
where corporate volunteering programs should be placed
in the corporate structure, and their dual role as a corpo-
rate social responsibility initiative and a human resources
development program. Discussions are currently under-
way at Pfizer to integrate the GHF program with other
management development initiatives, in part to mitigate
gender imbalance but also to increase the sustainability of
the program by making it less reliant on the support of
any particular corporate "champions". Pfizer is also con-
sidering adding some shorter-term volunteering opportu-
nities in order to appeal to higher level managers and
executives who cannot be away from their job responsibil-
ities for longer periods. The higher-level volunteers would
be placed in relatively complex local organizations which
have previously hosted Fellows for longer periods and
shown capacity to integrate technical assistance effec-
tively. This approach would maximize the probability of
high impact assignments within the shorter time frame.
Another strategic issue raised by the evaluation results is
program design. The study raises the question of whether
Pfizer's strategy of tailored technical assistance working
with myriad local Partner Organizations is the best corpo-
rate investment in building human resource capacity in
developing countries. A key factor in operation of Pfizer's
corporate volunteering program has been the lack of a
"cookie cutter" approach to technical assistance. Pfizer
chose not to "project-ize" the Fellowship assistance by
defining strategic results areas in advance. Instead, the
program identifies local partners and starts from where
they are, addressing the unique needs of each individual
organization. This strategy creates management chal-
lenges. As the Partner Organizations vary in size, mission,
ownership, and years of experience, this means each Fel-
lowship may set unique goals, apply different approaches,
and engage in different activities with varying outputs.
While Pfizer has made efforts to encourage internal shar-
ing of technical approaches and dissemination of lessons
learned, there is still a risk of Fellows "reinventing the
wheel" in developing new systems when these exist in
similar programs with which the volunteer was not famil-
iar.
An alternative strategy to improve program effectiveness is
to focus on a more homogeneous set of partnerships or
technical assistance goals. Research sponsored through
the Brookings Initiative's Initiative on International Vol-
unteering may provide some guidance in this regard. The
Brookings Initiative's Corporate Engagement Working
Group has commissioned a white paper on international
corporate volunteering in an effort to document best prac-
tices for selection and deployment of volunteers and eval-
uation of program impact. Initial findings suggest that
some companies are focusing capacity-building assistance
on specific types of organizations or interventions. For
example, the multinational medical technology company
BD (Becton Dickinson Corporation) worked in collabora-
tion with the Zambian Catholic Medical Mission Board to
field 10 corporate volunteers for a two-week assignment
in 2005 and 2006 [23,24]. The volunteers installed labo-
ratory equipment and trained staff at five local facilities.
While the sustainability of this program or others like it is
not well documented, more focused programs such as
BD's have intuitive appeal. By reducing the breadth of
capacity building assistance, the program may be able to
offer more relevant and tailored technical assistance, and
can train and orient volunteers more efficiently. A
"hybrid" design approach (narrowly targeted but also
open-ended) is illustrated by the public-private partner-
ship between the international transport corporation TNT
and the UN World Food Program. This program is focused
on the function of delivering World Food Program sup-
plies and aid during disasters, but the capacity building
technical assistance provided by TNT is varied and tai-
lored to the specific field office being assisted and its spe-
cific mission, goals, history and resources [20]. Pfizer is
currently considering changes to their international vol-
unteering program to sharpen the strategic focus.
More controversial is the challenge of deciding which
organizations to support through corporate volunteering.
Sending a succession of Fellows to well-managed, rela-
tively complex organizations that have made effective use
of previous Fellowships may increase impact; yet smaller
organizations also need capacity building help, especially
since these organizations can play an integral role in
achieving goals of equity and access for marginal popula-
tions. One possible strategy to include smaller organiza-
tions might be to encourage the creation of networks of
Partner Organizations within a given area or country,
allowing large and small organizations to share manage-
ment tools and encouraging collaborative improvement
efforts.
Methodological issues
A final question concerns the types of evaluation tools
and methods which are needed to measure the sustained
impact on the organizations receiving assistance. The GHF
program experience suggests a need to sensitize employee
volunteers to the benefits of measuring program impact
and documenting results. A follow-on research study
funded by the United States Agency for International
Development (USAID) Global Health Office and Pfizer isPage 9 of 11
(page number not for citation purposes)
Human Resources for Health 2007, 5:8 http://www.human-resources-health.com/content/5/1/8designed to collect measures of capacity building impact,
including more extensive development of an impact
typology such as the one presented here. The study will
also measure factors which may influence program
impact, including Fellow characteristics, Partner Organi-
zation level of development, and features of the Fellow-
ship itself (e.g. length, tasks, etc.).
Future evaluations might also try to systematically survey
all groups (Fellows, Supervisors, and Partners) and pose
questions in such a way that they cross-refer. This would
allow comparison of perceptions of impact. Discrepancies
might help identify specific ways to improve the matching
between Fellows and Partners, and better coordinate the
collaborations and mutual expectations.
Benefits for corporate partners
What did Pfizer get out of the program, and what benefits
might other corporations obtain by adopting public-pri-
vate partnerships based on corporate international volun-
teering? In recent years, public expectations have grown
regarding the role business should be playing in global
health. People expect private companies to be involved in
increasing access to services as a duty of corporate citizen-
ship. Observers have noted that companies can use phi-
lanthropy as a way to rebuild eroding trust and establish
the public acceptance needed to stabilize their market-
place [22,25]. Interviews with key opinion leaders in sev-
eral countries suggest that Pfizer's program may have had
a positive influence on the company's reputation,
although quite a few opinion leaders were unaware of the
program, or did not know that the Fellows were associated
with Pfizer.
The evaluation found that the Program had a positive
impact on the Fellows themselves, their professional
development, and the pride and satisfaction of the Fel-
lows' work groups at Pfizer. Fellows reported believing
that their experience dealing with sometimes inadequate
resources, uncertainty, and cultural differences will make
them better, more flexible managers. They expect the Fel-
lowship will give an advantage in future assignments and
promotions. Seventy-seven percent of Fellows felt the
effect on their professional development was positive.
Pfizer's commitment to the GHF Program made the Fel-
lows (and their co-workers) proud to be a Pfizer
employee. These findings are described in more detail
elsewhere [26].
This evaluation has several limitations. First, while we
made several attempts to contact Pfizer Fellows who had
subsequently left the company, we were only able to con-
tact one out of the nine Fellows no longer employed by
Pfizer. It is possible that these Fellows had different expe-
riences from those who are still at Pfizer, though it is
unlikely that this has affected the information reported by
Partner Organizations. Secondly, the evaluation was only
able to conduct site visits in five countries, including 60%
of Fellowship experiences. The experiences of Partner
Organizations not visited may be different. In addition,
although efforts were made to assure informants that
responses were confidential and anonymous, it is possible
that some respondents were reluctant to share criticism.
Finally, our typology of Fellowship impacts was created
retrospectively and must be interpreted with caution. Fur-
ther research is needed to test the reliability of this typol-
ogy.
Pfizer provided partial funding for this study, as described
in the Competing Interests section. Pfizer staff did not
have editorial control or review the manuscript before
submission, mitigating the potential for bias in reporting
results.
Conclusion
Public-private partnerships and corporate philanthropy
have significant resources to leverage toward expanding
health services in developing countries. In recent years,
corporate philanthropy has shifted to "interdependent
philanthropy", with the dual goal of addressing social
problems while also furthering the company's strategic
interests and expanding core business [13]. Strengthening
health services in poor countries is an area where interde-
pendent philanthropy can make a difference. More
research is needed to develop frameworks and methods
for evaluation of international corporate volunteering
programs. The lessons learned in evaluating such pro-
grams can help direct future investments to build capacity
in sustainable ways.
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